#cancer gene therapy market

[mitalipingale]

https://zekond.com/read-blog/58813_cancer-gene-therapy-market-size-overview-share-and-forecast-2031.html

The Cancer Gene Therapy Market in 2023 is US$ 2.64 billion, and is expected to reach US$ 14.42 billion by 2031 at a CAGR of 23.6%.

[iruchakalyan]

The Global Cancer Gene Therapy Market was valued at USD 2.80 Billion in 2023 and is estimated to reach USD 15.8 Billion by 2032, growing at a CAGR of 20.45 % from 2023 to 2032.

Cancer is a group of diseases that grow abnormal cells in the human body and can grow in any part of the body. Gene Therapy is a technique to prevent diseases, where the mutated genes are replaced by the specific genes causing the disease or are inactive in this gene. Cancer gene therapy is receiving high importance due to its high success rate during pre-clinical and clinical trials. The research and development on this are trying to replace the use of surgeries and drugs with gene therapy to treat cancer. The ongoing investment in research and development, and acceptance of gene therapy in cancer treatment is propelling this cancer gene therapy market during the forecast period. Biotechnology firms are increasing novel gene therapy vectors that increase levels of protein production or gene expansion, and reducing immunogenicity. According to National Center for Health Statistics, in 2023 there are 19,58,310 cancer cases in the U.S.

Further, the growing geriatric population, advanced product technology, increase in per capita disposable income, and emerging economies are the factors that are creating lucrative opportunities for the growing cancer gene therapy market.

Economic Impact of Covid-19:

The analysis of the COVID-19 recovery trajectory provides an overview of the main strategies that industries are implementing to respond to and recover from the economic crisis. It also focuses on the post-pandemic and pre-pandemic era of the Global Cancer Gene Therapy Market through PEST analysis, SWOT, Quantitative and Qualitative analysis, Attractive analysis, and DROs.

Key Players:

Novartis AG

Pfizer Inc.

Amgen Inc

Johnson & Johnson

AstraZeneca

GlaxoSmithKline plc

Gilead Science, Inc.

Abeona Therapeutics

Altor Bioscience Inc.

Celgene Inc.

Introgen Therapeutics Inc.

BioCancell Inc.

Oncogenex

Shanghai Sunway Biotech

ZioPharm Oncology

Others

The above key players in the Global Cancer Gene Therapy Market can be changed according to the client’s requirements.

Moreover, the key players aim towards expansion, joint ventures, collaboration, mergers, and acquisitions to advance capabilities in gene therapy.

Know More- https://nexbindinsight.com/pharmaceutical-and-healthcare/the-global-cancer-gene-therapy-market-was-valued-at-usd

[luckydige45]

As per the report from nova one advisor, the global cancer gene therapy market is valued at USD 2.45 billion in 2023 and is projected to reach a value of USD 12.75 billion by 2032 at a CAGR (Compound Annual Growth Rate) of 20.1% between 2023 and 2032

[afeelgoodblog]

The Best News of Last Week - March 27, 2023

🐢 - Why did the 90-year-old tortoise become a father? Because he finally came out of his shell!

1. New Mexico governor signs bill ending juvenile life sentences without parole

New Mexico Governor Michelle Lujan Grisham has signed a bill into law that prevents juvenile offenders from receiving life sentences without eligibility for parole. The bill, known as the No Life Sentences for Juveniles Act, allows offenders who committed crimes under the age of 18 and received life sentences to be eligible for parole hearings 15 to 25 years into their sentences.

This legislation also applies to juveniles found guilty of first-degree murder, even if they were tried as adults. The move puts New Mexico in a group of at least 24 other states and Washington, DC, that have enacted similar measures following a 2021 Supreme Court ruling.

2. Promising pill completely eliminates cancer in 18 leukaemia patients

An experimental pill called revumenib has shown promise in curing terminal leukemia patients who were not responding to treatment in a long-awaited clinical trial in the United States. The drug works by inhibiting a specific protein called menin, which is involved in the machinery that gets hijacked by leukemia cells and causes normal blood cells to turn into cancerous ones.

The pill targets the most common mutation in acute myeloid leukemia, a gene called NPM1, and a less common fusion called KMT2A. The US Food and Drug Administration granted revumenib "breakthrough therapy designation" to fast-track its development and regulatory review based on the promising results of the trial.

3. Spain passes law against domestic animal abuse

Spain has passed a new law on animal welfare, accompanied by a reform of the penal code that increases prison sentences for those mistreating animals. The law will make compulsory training for dog owners, and will prohibit them from leaving their dogs alone for more than 24 hours.

It also mandates the sterilisation of cats, with exceptions for farms, and increases the penalties for mistreatment of animals to up to two years in prison, or three years in the event of aggravating circumstances.

4. Bravery medals for women who raced into 'rough, crazy' surf to save drowning girls

Elyse Partridge (far left) and Bella Broadley (far right) raced into dangerous surf to save Chloe and Violet from drowning.(ABC North Coast: Hannah Ross)

Bella Broadley and Elyse Partridge saved two 11-year-old girls from drowning at Angels Beach near Ballina, an unpatrolled beach in Australia. The younger girls, Chloe and Violet, became trapped in a rip and overwhelmed by waves and the current. Bella and Elyse jumped into action, using an esky lid as a flotation device to help them swim to the girls. Elyse helped Chloe back to shore while Bella swam further out to help Violet.

Elyse and Bella were on Wednesday named on the Governor General's Australian Bravery Decorations Honours List, which recognised 66 Australians for acts of bravery.

5. Almost every cat featured in viral Tik Tok posted by Kansas City animal shelter adopted

Let's find homes for the rest

6. A 90-year-old tortoise named Mr. Pickles just became a father of 3. It's a big 'dill'

These critically endangered tortoises are native to Madagascar and have seen their numbers decline due to over-collection for illegal sales on the black market. Captive breeding programs have helped produce new radiated tortoises, but the species still faces extinction in the wild.

That's why the arrival of these hatchlings, born to 90-year-old Mr. Pickles and his 53-year-old partner Mrs. Pickles, is such great news. Mr. Pickles is considered the most genetically valuable radiated tortoise in the Association of Zoos and Aquariums' Species Survival Plan, and the births represent a significant contribution to the survival of the species.

7. EU strikes ‘ground-breaking’ deal to cut maritime emissions

The European Parliament and EU ministers have agreed on a new law to cut emissions in the maritime sector. The law aims to reduce ship emissions by 2% as of 2025 and 80% as of 2050, covering greenhouse gas, methane, and nitrous oxide emissions.

The European Commission will review the law in 2028 and will decide whether to place carbon-cutting requirements on smaller ships. The agreement will also require containerships and passenger ships docking at major EU ports to plug into the on-shore power supply as of 2030. Penalties collected from those that fail to meet the targets will be allocated to projects focused on decarbonising the maritime sector.

- - - -

That's it for this week :)

This newsletter will always be free. If you liked this post you can support me with a small kofi donation:

Buy me a coffee ❤️

Also don’t forget to share this post with your friends.

[dailyanarchistposts]

Biotechnology and the future of humanity

Animals Are Commodities Too

Under slavery human individuals are owned, are property. Under capitalism workers aren’t owned but they have to sell their labour/time/creativity because capitalists own everything (land, the means of production, transport and communication etc) that would enable people to live outside of wage labour and the market place. Now, instead of individuals owning non-human animals as part of their subsistence, corporations are claiming the right to ‘own’ whole species of animals. This process of patenting life can be traced back to the 1980 US Supreme Court ruling, which stated that a GM bacterium (modified to digest oil) could be patented. Not just that one bacterium of course but the whole, created species. In 1985 the US Patent and Trademark Office ruled that GM plants, seeds and plant tissues could be patented. Now the corporations can demand royalties and licence payments every time farmers use those plants or seeds. Monsanto holds a patent on (i.e. owns and rents out) all GM cotton and soya. Patents have been granted on biological characteristics of plants as well. For example, a patent has been issued to Sungene for a variety of sunflower that has a high oleic acid content. But the patent covers the characteristic as well as the genes that code for it, so any plant breeder who achieves the same result by traditional methods could be sued.

In 1987 animals joined the biotech market place when a Harvard biologist patented ‘oncomouse’, a GM organism (mouse) predisposed to develop cancer for use in medical ‘research’. By 1997 40 GM ‘species’ of animal had been patented, including turkey, nematodes, mice and rabbits. Hundreds of other patents are pending on pigs, cows, fish, sheep and monkeys among others. In 1976 a leukaemia patient named John Moore had his cancerous spleen removed under surgery at the University of California. Without his knowledge or consent some of the cells from his spleen were cultured and found to produce a protein which could be used in the manufacture of anti-cancer drugs. The estimated value of this cell-line to the pharmaceutical industry is $3 billion. In 1984 the California Supreme Court ruled that he was not entitled to any of these profits.

A US company called Biocyte holds a patent on (owns) all umbilical cord cells. Systemix Inc has a patent on (owns) all human bone marrow stem cells, these being the progenitors of all cells in the blood. The worldwide market for cell lines and tissue cultures was estimated to be worth $426.7 million to the corporations in 1996. Not only cells but also fragments of DNA can be patented (owned) in this way. Incyte, for example, has applied for patents on 1.2 million fragments of human DNA. The logic of this is that ‘genes for’ particular diseases such as cystic fibrosis, diabetes, various cancers etc could become the property of pharmaceutical companies who could then make huge profits on tests for such genes and genebased therapies. There is no space here to get into a lengthy criticism of the reductionist idea that individual genes simply map onto well-defined physical traits underlying the whole theory and practice of GM. It’s enough to say that research into patenting (owning), for example, a supposed’ breast cancer gene’ is of little benefit to humanity if it is true, as some scientists have estimated, that 90% of breast cancers are unrelated to genetics but are triggered by environmental pollution, diet and lifestyle factors. So what’s new? Capitalism, indeed class-society in general, always seizes the living and turns it into profit and power, declares ownership where previously there was only life: from the enclosure of the commons to the seizing of millions of human beings from Africa to be slaves to the current looting of tropical biodiversity for use in the biotech labs.

[health-views-updates]

Cell Therapy Market Report: Size, Growth, and Key Trends to 2032

The Cell Therapy Market Revenue was valued at USD 4.65 billion in 2023 and is expected to reach an impressive USD 28.98 billion by 2032, growing at a staggering CAGR of 22.55% over the forecast period 2024-2032. This robust growth is fueled by advancements in regenerative medicine, increasing prevalence of chronic diseases, and the rising demand for personalized treatment solutions.

Key Drivers of Growth

The cell therapy market is experiencing unprecedented expansion driven by breakthroughs in research and development (R&D) and the rising number of clinical trials exploring the therapeutic potential of cellular therapies. These therapies, which include stem cell and CAR-T cell treatments, are proving to be transformative in addressing a wide range of medical conditions, including cancer, autoimmune diseases, and genetic disorders.

Moreover, regulatory agencies worldwide are increasingly supporting the development and approval of innovative cell-based therapies. The accelerated approval pathways and favorable reimbursement policies in key regions are fostering the adoption of cell therapy in mainstream healthcare. The convergence of advanced technologies, such as CRISPR gene editing, with cell therapy is further propelling the market toward significant innovation.

Regional Insights

North America continues to lead the market due to its robust healthcare infrastructure, substantial investment in R&D, and the presence of major biopharmaceutical companies. Meanwhile, the Asia-Pacific region is emerging as a high-growth market, driven by government initiatives to promote biotechnology, increasing healthcare expenditures, and a growing focus on addressing unmet medical needs.

Get Free Sample Report@ https://www.snsinsider.com/sample-request/4482

Future Outlook

The cell therapy market is expected to experience exponential growth as technological advancements and increasing awareness of these therapies' potential reshape the treatment landscape. The integration of artificial intelligence (AI) and data analytics in cell therapy research is expected to enhance precision and accelerate drug development processes. Furthermore, collaborative efforts between academia, healthcare providers, and industry players will likely contribute to faster adoption and commercialization of innovative solutions.

About SNS Insider

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Contact Us

Akash Anand – Head of Business Development & Strategy Email: info@snsinsider.com Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)

[mitalipingale]

https://tannda.net/read-blog/74731_cancer-gene-therapy-market-size-overview-share-and-forecast-2031.html

The Cancer Gene Therapy Market in 2023 is US$ 2.64 billion, and is expected to reach US$ 14.42 billion by 2031 at a CAGR of 23.6%.

[jayanthitbrc]

Global CRISPR And Cas Gene Market Analysis 2024: Size Forecast and Growth Prospects

The crispr and cas gene global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

CRISPR And Cas Gene Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The crispr and cas gene market size has grown exponentially in recent years. It will grow from $3.28 billion in 2023 to $3.97 billion in 2024 at a compound annual growth rate (CAGR) of 21.3%. The growth in the historic period can be attributed to increased consumer awareness, shift in consumer values, rise in celebrity endorsements, rise of veganism, increased social media influence.

The crispr and cas gene market size is expected to see exponential growth in the next few years. It will grow to $8.37 billion in 2028 at a compound annual growth rate (CAGR) of 20.5%. The growth in the forecast period can be attributed to global expansion of bans, rising conscious consumerism, emergence of new brands, consumer education initiatives, beauty inclusivity. Major trends in the forecast period include technology advancements, product innovations, circular beauty economy, men's grooming segment, social justice and ethical sourcing.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/crispr-and-cas-gene-global-market-report

Scope Of CRISPR And Cas Gene Market The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

CRISPR And Cas Gene Market Overview

Market Drivers - A growing focus on personalized therapy is expected to propel the growth of the CRISPR and Cas gene markets going forward. Personalized therapy refers to a medical model that uses an individual's genetic profile to guide decisions made concerning the diagnosis, treatment, and prevention of disease. CRISPR and the Cas gene, particularly Cas9, are used in personalized medicine, enabling precise modifications to an individual's genetic material and holding promise for breakthroughs in developing tailored therapies for genetic disorders, cancer, and various medical conditions. For instance, in January 2023, according to the Personalized Medicine Coalition, a US-based professional membership organization, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022. Out of the 35 therapeutic NMEs, approximately 34%, which amounts to 12 of them, are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Therefore, the rising demand for personalized therapy will drive the growth of the CRISPR and Cas gene markets.

Market Trends - Major companies operating in the CRISPR and Cas gene markets are developing innovative products such as CRISPR-based cell-based gene therapy to enhance product offerings and gain a competitive advantage. CRISPR-based cell-based gene therapy involves using the CRISPR gene-editing technology to modify or correct genetic material within cells, offering a targeted and potentially revolutionary approach to treating genetic disorders, diseases, and other medical conditions at the cellular level. For instance, in December 2023, Vertex Pharmaceuticals Incorporated, a US-based biopharmaceutical company, received approval for CASGEVY (exagamglogene autotemcel [exa-cel]) from the U.S. Food and Drug Administration (FDA). CASGEVY is a CRISPR/Cas9 genome-edited gene therapy for the management of sickle cell disease (SCD) in individuals aged 12 and above who have recurrent vaso-occlusive crises. CASGEVY is a first-of-its-kind medication that has the potential to be a one-time transformational therapy for qualified sickle cell patients. CASGEVY administration necessitates specific training in stem cell transplantation, hence, Vertex is collaborating with experienced institutions to create a network of independently owned, approved treatment centers (ATCs) across the United States to provide CASGEVY to patients.

The crispr and cas gene market covered in this report is segmented –

1) By Product Type: Kits And Enzymes, Libraries, Design Tool, Antibodies, Other Products Types 2) By Service Type: Cell Line Engineering, gRNA Design, Microbial Gene Editing, DNA Synthesis 3) By Application: Clinical, Financial, Operational And Administrative 4) By End Use: Biotechnology And Pharmaceutical Companies, Academics And Government Research Institutes, Contract Research Organizations (CROs)

Get an inside scoop of the crispr and cas gene market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13632&type=smp

Regional Insights - North America was the largest region in the CRISPR and Cas gene market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the crispr and cas gene market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies - Major companies operating in the crispr and cas gene market report are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc, AstraZeneca plc., Danaher Corporation, Quest Diagnostics, Lonza Group AG, Bio-Rad Laboratories Inc., eGenesis, Novartis Institutes for BioMedical Research, Myriad Genetics Inc., GenScript, Takara Bio Inc., 23andMe Inc., Merck KGaA, Color Genomics Inc., Horizon Discovery Group Plc, Beam Therapeutics Inc, Intellia Therapeutics Inc., New England BioLabs, Recursion Pharmaceuticals Inc, Caribou Biosciences Inc., Cellectis S.A., Editas Medicine Inc.

Table of Contents 1. Executive Summary 2. CRISPR And Cas Gene Market Report Structure 3. CRISPR And Cas Gene Market Trends And Strategies 4. CRISPR And Cas Gene Market – Macro Economic Scenario 5. CRISPR And Cas Gene Market Size And Growth ….. 27. CRISPR And Cas Gene Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us: The Business Research Company Europe: +44 207 1930 708 Asia: +91 88972 63534 Americas: +1 315 623 0293 Email: info@tbrc.info

Follow Us On: LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[insightfulblogz]

Prescription Drugs Market Drivers, Revenue And Forecast to 2032

Prescription drugs are a crucial segment of the global healthcare industry, encompassing a wide range of medications that are prescribed by healthcare professionals to treat various diseases, conditions, and symptoms. These drugs are regulated by government authorities such as the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency), ensuring their safety, efficacy, and quality. Prescription drugs are typically more potent and targeted than over-the-counter (OTC) drugs and often form the backbone of treatment for chronic diseases such as cancer, diabetes, hypertension, and mental health disorders. The growing global healthcare burden, especially due to the aging population, rising incidences of chronic diseases, and advancements in drug development, has led to a steady demand for prescription drugs worldwide.

The Prescription Drugs Market size was valued at USD 1162.60 Billion In 2023 & is estimated to reach USD 2173.61 Billion by 2032 and increase at a CAGR of 7.2% between 2024 and 2032.

Future Scope

The future of the prescription drugs market is promising, driven by innovation in drug development, personalized medicine, and increasing global healthcare access. As biopharmaceuticals and biologics continue to expand, the demand for prescription medications will remain strong. Additionally, advancements in biotechnology, genomics, and precision medicine will lead to more tailored and effective treatments, especially in oncology and rare diseases. The global push toward improving healthcare infrastructure, especially in emerging markets, and the growing awareness of the importance of preventive healthcare will further fuel market growth. Furthermore, digital health solutions and telemedicine are expected to create new avenues for prescribing and distributing drugs, making treatment more accessible, efficient, and personalized.

Emerging Trends

One of the most significant trends in the prescription drug market is the shift toward biologics and biosimilars. These drugs, derived from living organisms, have revolutionized the treatment of various diseases, particularly cancer, autoimmune disorders, and genetic conditions. Biosimilars, which are highly similar versions of approved biologic drugs, are expected to increase in adoption due to their cost-effectiveness compared to original biologics. Additionally, there is a growing trend of digital health applications, including mobile health apps and AI-based platforms, being used to monitor drug adherence and provide personalized treatment regimens. Another emerging trend is the rise of gene therapies, which hold the potential to treat genetic diseases at the root cause, offering a new frontier in prescription drug development.

Drivers

Several factors are driving the growth of the prescription drugs market. First and foremost, the increasing global prevalence of chronic diseases such as diabetes, cardiovascular disorders, and cancer is significantly boosting demand for prescription medications. Additionally, advancements in medical research, biotechnology, and pharmacology are leading to the development of more effective and targeted drugs. The aging global population is another crucial driver, as older individuals are more likely to suffer from chronic conditions that require prescription medications. Furthermore, increasing healthcare access in emerging economies, along with rising disposable incomes, has expanded the reach of prescription drugs to new patient populations, driving market expansion. Government initiatives aimed at improving healthcare and providing access to life-saving drugs also support market growth.

Restraints

Despite its growth, the prescription drugs market faces several challenges. One of the most significant restraints is the high cost of developing new drugs, which involves extensive clinical trials, regulatory approvals, and significant financial investment. This results in high drug prices, particularly for novel treatments, putting them out of reach for many patients. The market also faces the challenge of stringent regulatory requirements and intellectual property protections that can delay the entry of generics and biosimilars, limiting competition. Additionally, concerns over drug side effects, safety, and the potential for misuse, especially with opioid medications, present ongoing issues. Lastly, the global challenge of counterfeit drugs, which can undermine patient trust and safety, remains a persistent concern.

Key Points

The prescription drugs market is critical to global healthcare, offering targeted treatments for a wide range of diseases and conditions.

Biopharmaceuticals and biologics, along with biosimilars, are leading the way in terms of innovation in the market.

Precision medicine and personalized drug therapies are expected to dominate future drug development trends.

The global rise in chronic diseases, an aging population, and expanding healthcare access are significant market drivers.

High costs of drug development and concerns over safety and counterfeit drugs remain key challenges for the industry.

Digital health solutions and the rise of telemedicine are transforming how prescription drugs are prescribed and managed.

The prescription drugs market continues to evolve with advancements in biotechnology, personalized medicine, and digital health solutions, offering new opportunities while addressing critical healthcare needs across the globe.

[stevenwilliam12]

5 Emerging Cell and Gene Therapies That Could Revolutionize Parkinson’s Disease Treatment

Parkinson's disease is a progressive neurodegenerative disorder characterized by the loss of dopamine-producing neurons in the brain. Symptoms include tremors, rigidity, bradykinesia, and postural instability. Despite advancements in medications and deep brain stimulation, no treatment currently halts disease progression. However, emerging cell and gene therapies offer a promising avenue for addressing the root causes of Parkinson’s disease.

Emerging Cell and Gene Therapies on the Horizon:

Dopaminergic Neuron Replacement Therapy: This therapy focuses on generating dopamine-producing neurons from stem cells and transplanting them into the brain to restore dopamine levels. Clinical trials in the Parkinson’s disease pipeline are exploring pluripotent stem cell-derived dopaminergic neurons.

AAV-GAD Gene Therapy: Adeno-associated virus (AAV)-based gene therapy delivers the GAD (glutamic acid decarboxylase) gene to affected brain regions, enhancing GABA production to reduce motor symptoms. Parkinson's disease clinical trials have shown promising safety and efficacy data.

Exosome-Based Therapeutics: Utilizing engineered exosomes to deliver therapeutic proteins or genetic material to the brain, this therapy aims to halt neuroinflammation and oxidative stress, which exacerbate Parkinson's disease progression.

CRISPR-Cas9 Gene Editing: This revolutionary technology targets specific genes implicated in Parkinson’s disease, such as those linked to alpha-synuclein accumulation. Preclinical models indicate that CRISPR-based approaches may reduce pathological protein aggregation.

Glial Cell Line-Derived Neurotrophic Factor (GDNF) Delivery: Gene therapy using viral vectors to deliver GDNF, a neuroprotective protein, to damaged brain areas shows potential for regenerating dopaminergic neurons and improving motor functions.

Future Outlook of Cell and Gene Therapies in Parkinson’s Disease Treatment

The growing Parkinson's disease market is witnessing unprecedented innovation with these emerging therapies. As research advances, clinical trials for Parkinson's disease treatments are expanding, focusing on long-term safety and efficacy. Regulatory bodies and pharmaceutical companies are collaborating to accelerate the development of therapies in the Parkinson's disease pipeline.

Conclusion:

Parkinson’s Disease Cell and Gene Therapy represents a paradigm shift, offering hope for slowing or halting disease progression. With advancements in technology and ongoing trials, the future of Parkinson's disease treatment is promising, potentially transforming millions of lives. Continued investment and collaboration in this field are critical to achieving these breakthroughs.

Latest Reports

Failed Back Surgery Syndrome Market | Familial Hypercholesterolemia Market | Familial Lipoprotein Lipase Deficiency Pipeline | Fibrocystic Breast Condition Market | Fucosidosis Market | Glycogen Storage Disease Market | Head And Neck Cancer Market | Hemorrhagic Cystitis Market | Hepatic Encephalopathy Epidemiology Forecast | Hepatic Encephalopathy Market | Her2-negative Breast Cancer Market | Her2-positive Early Breast Cancer Market | Hiatal Hernia Market | Hospital-acquired And Ventilator-associated Bacterial Pneumonia Habp/vabp Market | Hpv16+ Cancer Market | Hypereosinophilic Syndrome Market | Hyperkalemia Market | Hypertrophic Cardiomyopathy Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Implantable Infusion Pumps Market | Intracranial Arterial Diseases Market 

[exp-market-research111]

Carcinoid Tumor Drug Pipeline Analysis Report 2024

Carcinoid Tumor Market Outlook

Carcinoid tumors are uncommon, representing roughly 0.5% of all cancers. Typically diagnosed in individuals around their early 60s, these tumors mainly occur in the gastrointestinal system. In the United States, approximately 8,000 new cases of carcinoid tumors are reported annually. Treatment options include surgical intervention, chemotherapy, targeted therapies, and the development of new immunotherapies. These innovative treatments focus on slowing tumour growth and enhancing patient prognosis.

Carcinoid Tumor: Introduction

Carcinoid tumours are rare, slow-growing neuroendocrine tumours that typically develop in the gastrointestinal tract, lungs, or other endocrine organs. These tumours secrete hormones, such as serotonin, which can lead to a condition called carcinoid syndrome, characterised by symptoms like diarrhoea, flushing, and wheezing. Diagnosis often occurs late due to the insidious nature of symptoms, making treatment challenging. The development of new therapies focuses on controlling tumour growth, managing hormone secretion, and improving patient quality of life. Ongoing clinical trials and drug innovations are crucial to addressing the unmet needs in the treatment of these rare tumours.

Get a Free Sample Report with Table of Contents: https://www.expertmarketresearch.com/clinical-trials/carcinoid-tumor-drug-pipeline-analysis/requestsample

Carcinoid Tumor Treatment Overview

Carcinoid tumours are typically treated with surgical resection if possible, alongside therapies that control tumour growth and hormone secretion. The main treatment approaches include somatostatin analogues to reduce symptoms, chemotherapy for advanced disease, and targeted therapies. Early-stage disease may be managed with surgery alone, while more advanced stages require a combination of therapies, including systemic treatments and novel therapies under investigation.

Treatment options include somatostatin analogues such as octreotide and lanreotide to manage symptoms. Other approaches include chemotherapy, targeted therapies, and peptide receptor radionuclide therapy (PRRT). Targeted drugs, such as mTOR inhibitors and tyrosine kinase inhibitors, are emerging as promising options in advanced or resistant cases.

Drug Pipeline Therapeutic Assessment

Analysis by Route of Administration

Oral

Parenteral

Others

Analysis by Phase 

Preclinical Phase

Phase I

Phase II 

Phase III 

Phase IV 

Analysis by Drug Class

Monoclonal Antibody 

Peptides 

Polymer 

Small Molecule 

Gene Therapy

Carcinoid Tumor Drug Classes

Carcinoid tumor treatments utilise a range of drug classes, each designed to target specific pathways and mechanisms involved in cancer growth and survival. These diverse classes enhance the effectiveness of therapy and contribute to personalised treatment strategies. Understanding these drug classes is essential for optimising patient outcomes.

Monoclonal Antibody

Monoclonal antibodies are laboratory-engineered molecules designed to target specific antigens on the surface of tumour cells, which helps to block their growth and enhances the immune system's ability to destroy them. In carcinoid tumours, these antibodies may target receptors that drive hormone secretion or tumour proliferation, improving disease control. By blocking key growth signals or immune evasion mechanisms, monoclonal antibodies offer an effective and precise treatment strategy for managing advanced or metastatic carcinoid tumours.

Peptides

Peptide-based therapies consist of short chains of amino acids that can interfere with the processes responsible for tumour growth. In carcinoid tumours, somatostatin analogues are commonly used, which bind to specific receptors on the tumour cells, inhibiting the release of excess hormones such as serotonin. These therapies help to manage symptoms like flushing and diarrhoea associated with carcinoid syndrome, and stabilise tumour growth, offering symptom relief and improving patients’ quality of life.

Polymer

Polymers play an important role in cancer therapy by improving the delivery and stability of drugs. In carcinoid tumours, polymer-based drug delivery systems are used to target therapies more efficiently to the tumour site. This enhances the effectiveness of drugs by increasing their concentration at the tumor while reducing side effects on healthy tissues. Such advanced delivery mechanisms help to improve therapeutic outcomes, particularly for patients with advanced, resistant, or metastatic disease.

Small Molecule

Small molecules are drugs that are small enough to enter cells and interfere with cellular pathways responsible for tumour growth and survival. In carcinoid tumours, small molecules target specific signalling pathways involved in tumour proliferation and hormone production. By modulating these pathways, small molecules can help slow down tumour growth, manage symptoms, and provide an effective option for treating progressive or metastatic carcinoid tumours, where traditional therapies may be less effective.

Gene Therapy

Gene therapy aims to address the underlying genetic causes of cancer by modifying or replacing defective genes in tumour cells. For carcinoid tumours, gene therapy is being investigated to either restore normal cellular function or enhance the immune system’s ability to recognise and destroy tumour cells. This approach holds promise for offering long-term solutions in treating hard-to-treat, resistant cases of carcinoid tumours by targeting the molecular drivers of tumour growth.

Carcinoid Tumor- Pipeline Drug Profiles 

This section provides an overview of the various drugs used to treat carcinoid tumor. It covers their classifications, mechanisms of action, and methods of administration, offering essential insights for effective treatment strategies.

40 mg Paltusotine

Paltusotine is a selective somatostatin receptor type 2 agonist that is being investigated for its potential to control hormone secretion in patients with carcinoid syndrome. By reducing the serum levels of serotonin, it helps to manage the symptoms of diarrhoea, flushing, and wheezing associated with the syndrome. Clinical trials have shown promising results, especially for patients who have not responded to other standard therapies, making it a potential new option for long-term management.

Pasireotide (SOM230)

Pasireotide is a multireceptor-targeted somatostatin analogue used to manage the symptoms associated with neuroendocrine tumours, including carcinoid syndrome. It works by binding to somatostatin receptors and inhibiting the release of hormones like serotonin, which causes symptoms like diarrhoea and flushing. Pasireotide has shown efficacy in clinical trials, particularly in patients whose symptoms are not adequately controlled by first-line treatments. It offers an alternative therapeutic option for patients with advanced or resistant cases.

Quarfloxin

Quarfloxin is an investigational small molecule that targets the mitochondrial DNA replication machinery in cancer cells, causing tumour cell death. In carcinoid tumours, quarfloxin is being evaluated for its potential to inhibit tumour growth, particularly in patients with advanced or metastatic disease. Early clinical trials are assessing the drug’s safety and efficacy, and its combination with other therapies is being explored to improve overall treatment outcomes and manage resistant cases of carcinoid tumour.

Carcinoid Tumor: Competitor Landscape

The key features of the report include patent analysis, clinical trials, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 Novartis Pharmaceuticals

Headquartered in Basel, Switzerland, Novartis is a global leader in pharmaceutical innovation, with a strong presence in the oncology space. The company is known for its contributions to neuroendocrine tumour treatments, including the development of Pasireotide (SOM230) for managing carcinoid syndrome. Novartis continues to advance its research into targeted therapies and combination treatments, aiming to improve survival and quality of life for patients with rare, difficult-to-treat cancers such as carcinoid tumours.

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, located in Rockville, Maryland, USA, is a biotechnology company focused on the development of novel therapies for rare and difficult-to-treat cancers, including carcinoid tumours. The company’s pipeline includes therapies designed to target tumour growth and hormone secretion in neuroendocrine cancers. By developing precision medicine approaches, CASI aims to provide more effective treatment options for patients with advanced or refractory cases of carcinoid tumours, addressing an unmet need in this area of oncology.

Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals, headquartered in San Diego, California, USA, is a leading biotechnology firm focused on the development of innovative treatments for endocrine diseases, including carcinoid tumours. The company is advancing several drug candidates that aim to modulate hormonal pathways and inhibit tumour growth. Crinetics’ approach to precision medicine aims to provide more personalised and effective treatments for patients with neuroendocrine cancers, and their research is expected to significantly improve treatment outcomes for carcinoid tumour patients.

Other key players in the landscape include Molecular Insight Pharmaceuticals, Inc., Neotropix, Ipsen, Cylene Pharmaceuticals, Lexicon Pharmaceuticals, TerSera Therapeutics LLC, Trio Medicines Ltd., and Endo Pharmaceuticals.

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report..

[shubhamimarc]

Switzerland Pharmaceutical Market Demand, Growth and Industry Trends 2024-32

Switzerland Pharmaceutical Market Overview

Base Year: 2023

Historical Years: 2018-2023                  

Forecast Years: 2024-2032

Market Growth Rate: 5.70% (2024-2032)

The Switzerland pharmaceutical market is driven by strong R&D investments, a robust healthcare infrastructure, and the presence of global pharmaceutical giants. According to the latest report by IMARC Group, The Switzerland pharmaceutical market size is projected to exhibit a growth rate (CAGR) of 5.70% during ​2024-2032​.

Download sample copy of the Report: https://www.imarcgroup.com/switzerland-pharmaceutical-market/requestsample

Switzerland Pharmaceutical Market Trends and Drivers:

The Switzerland pharmaceutical market is a significant contributor to the country's economy, thanks to its excellent R&D capabilities and emphasis on innovation. The market benefits from Switzerland's highly qualified workforce, world-class infrastructure, and favorable regulatory environment, which attract large investments from multinational pharmaceutical corporations. Furthermore, the Swiss government's emphasis on healthcare innovation, together with its well-established healthcare system, helps to drive the expansion of the Switzerland pharmaceutical market. In addition to this, the need for advanced medicines, such as biologics and personalized medicine, is increasing as the country's aging population raises the prevalence of chronic diseases like cancer, cardiovascular disease, and diabetes.

Emerging trends in the Switzerland pharmaceutical market include the development of cutting-edge technologies such as gene therapy, cell therapy, and mRNA-based treatments. There is also a growing focus on digital health solutions, including telemedicine and health monitoring apps, to enhance patient care and optimize treatment outcomes. In line with these factors, sustainability initiatives are gaining momentum, with companies adopting eco-friendly manufacturing processes and reducing carbon footprints in line with global environmental goals. Additionally, strategic collaborations and partnerships between pharmaceutical firms, academic institutions, and biotech startups are fostering innovation and accelerating the commercialization of new therapies. Consequently, these factors, combined with supportive government policies and a strong intellectual property framework, are expected to drive the growth of the Switzerland pharmaceutical market in the coming years.

IMARCs report provides a deep dive into the market analysis, outlining the current trends, underlying Switzerland pharmaceutical market demand, and growth trajectories.

Switzerland Pharmaceutical Industry Segmentation:

The report has segmented the market into the following categories:

Type Insights:

Pharmaceutical Drugs

Cardiovascular Drugs

Dermatology Drugs

Gastrointestinal Drugs

Genito-Urinary Drugs

Hematology Drugs

Anti-Infective Drugs

Metabolic Disorder Drugs

Musculoskeletal Disorder Drugs

Central Nervous System Drugs

Oncology Drugs

Ophthalmology Drugs

Respiratory Diseases Drugs

Biologics           

Monoclonal Antibodies (MAbS)

Therapeutic Proteins

Vaccines

Nature Insights:

Organic

Conventional

Regional Insights:

Zurich

Espace Mittelland

Lake Geneva Region

Northwestern Switzerland

Eastern Switzerland

Central Switzerland

Ticino

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key highlights of the Report:

Market Performance (2018-2023)

Market Outlook (2024-2032)

COVID-19 Impact on the Market

Porter’s Five Forces Analysis

Strategic Recommendations

Historical, Current and Future Market Trends

Market Drivers and Success Factors

SWOT Analysis

Structure of the Market

Value Chain Analysis

Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145

[snehalblog]

Gene Therapy Market: Revolutionizing Modern Healthcare Through Cutting-Edge Innovations - UnivDatos

In the ever-evolving landscape of medical science, gene therapy stands as a beacon of hope. This groundbreaking field has witnessed remarkable progress in recent years, offering potential solutions to a wide range of genetic disorders and diseases. Gene therapy holds the promise of altering the very fabric of our biology, offering a glimpse into a future where debilitating illnesses can be treated at their root cause. In this article, we will explore the demand for gene therapy, its applications, the associated costs, the intricacies of manufacturing, and ultimately, its profound impact on the future of medicine.

Request To Download Sample of This Strategic Report - https://univdatos.com/get-a-free-sample-form-php/?product_id=47863&utm_source=LinkSJ&utm_medium=Snehal&utm_campaign=Snehal&utm_id=snehal

Gene Therapy Demand:

The demand for gene therapy has been steadily increasing as researchers and medical professionals recognize its potential to transform the way we treat genetic diseases. Traditional surgical instruments are becoming less relevant in this field, as gene therapy relies on the manipulation of genetic material rather than physical surgical procedures. However, specialized tools are still necessary for the delivery of gene therapies into the body.

One such instrument is the viral vector, which is used to transport therapeutic genetic material into the target cells. These vectors are typically derived from harmless viruses that have been modified to carry the desired genetic payload. The demand for these viral vectors has surged, leading to advancements in their production and delivery systems.

Applications of Gene Therapy:

Gene therapy has a wide range of applications that extend beyond just treating genetic disorders. Some of the key areas where gene therapy is making a significant impact include:

1. Genetic Disorders: Gene therapy offers the potential to cure or alleviate the symptoms of various genetic diseases, including cystic fibrosis, muscular dystrophy, and sickle cell anemia.

2. Cancer Treatment: Researchers are developing gene therapies to target and destroy cancer cells while sparing healthy ones. CAR-T cell therapy is a prime example, where a patient's T cells are engineered to attack cancer cells.

3. Neurological Disorders: In conditions like Parkinson's and Alzheimer's disease, gene therapy holds promise for slowing or even reversing the progression of these devastating conditions.

4. Rare Diseases: Gene therapy can address rare diseases caused by specific genetic mutations that were previously untreatable.

5. Infectious Diseases: Gene therapy can be used to enhance the body's immune response to infectious agents, offering potential treatments for HIV and other viral infections.

Cost of Gene Therapy:

While gene therapy holds immense promise, it is not without its challenges, one of the most significant being cost. The development and manufacturing of gene therapies involve intricate processes and specialized equipment, which can drive up expenses considerably.

One of the factors contributing to the high cost of gene therapy is the need for personalized treatments. Each patient's genetic makeup is unique, and designing a therapy tailored to an individual's genetic profile requires extensive research and development. Consequently, the initial cost of developing gene therapies can be prohibitively high.

Additionally, the manufacturing process for gene therapies is complex and often requires stringent quality control measures. This includes ensuring the consistency and purity of the viral vectors used for delivery. These factors contribute to the overall cost of gene therapy, making it a challenge for many patients and healthcare systems to afford.

Manufacturing Gene Therapies:

Manufacturing gene therapies is a complex and highly regulated process. It involves several key steps, including:

The viral vectors used to carry therapeutic genes must be produced at a large scale, requiring specialized bioreactors and cell culture systems.

The therapeutic genes are carefully designed and inserted into the viral vectors, a process that demands precision and expertise.

Stringent quality control measures are in place to ensure the safety and efficacy of the gene therapy products. This includes rigorous testing for purity, potency, and sterility.

The final gene therapy product is carefully packaged for delivery to healthcare facilities, where it will be administered to patients.

Gene therapy manufacturing must adhere to strict regulatory guidelines to ensure patient safety. The manufacturing facilities must meet Good Manufacturing Practices (GMP) standards to receive regulatory approval.

Ask for Report Customization - https://univdatos.com/get-a-free-sample-form-php/?product_id=47863&utm_source=LinkSJ&utm_medium=Snehal&utm_campaign=Snehal&utm_id=snehal

Conclusion

Gene therapy is on the cusp of revolutionizing the field of medicine. Its potential to cure genetic diseases, treat cancer, and address a wide range of other medical conditions is nothing short of remarkable. However, the high cost of development and manufacturing poses a significant challenge, limiting access to these life-changing therapies. As technology advances and manufacturing processes become more efficient, we can hope to see a reduction in the cost of gene therapy. This would open new possibilities for patients worldwide, allowing them to benefit from the incredible promise this field holds. In conclusion, gene therapy represents a monumental step forward in the quest to conquer genetic diseases and revolutionize the future of medicine. While challenges remain, the potential to alleviate human suffering and improve the quality of life for countless individuals is a goal worth pursuing. As researchers and healthcare professionals continue to push the boundaries of science, we may soon witness a world where gene therapy is accessible to all who need it, ushering in a new era of medical treatment and healing.

[latestmarketresearchnews]

DNA Synthesis Market 2030: Brief Analysis of Top Countries Data, Growth and Drivers

The global DNA synthesis market was valued at USD 3.13 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 15.30% from 2024 to 2030. This growth can largely be attributed to the increasing demand for DNA synthesis driven by its applications in several fields, including molecular biology, genetic engineering, and clinical diagnostics and therapeutics. Additionally, the rising need for research in drug discovery and personalized medicine is expected to further boost market expansion during the forecast period.

The market is also seeing moderate merger and acquisition activity, driven by factors such as the desire to enhance competitive positioning within the industry and the need for consolidation in a rapidly growing market. Companies are increasingly entering into collaborations to support advancements in research and development (R&D) in diagnostics and therapeutics. For example, in April 2023, Twist Bioscience, a leader in the DNA synthesis market, announced a collaboration with Astellas Pharma to assist in antibody discovery for immunotherapies. These strategic alliances are expected to strengthen the market's growth trajectory as they enhance innovation in gene-related research.

Gather more insights about the market drivers, restrains and growth of the DNA Synthesis Market

Regional Insights:

North America DNA Synthesis Market Trends

North America held the largest market share, accounting for 39.76% of the global revenue in 2023. The region’s growth is driven by heightened public awareness about genetic disorders, along with robust medical facilities and substantial investments in research and development. The prevalence of chronic illnesses, such as cancer, diabetes, and cardiovascular diseases, further amplifies the demand for DNA synthesis as a tool for understanding and treating these conditions. Additionally, North American market players are heavily investing in gene synthesis and gene therapy research, creating a fertile environment for growth. The presence of leading DNA synthesis companies in the region, along with continuous advancements in gene editing technologies, further supports regional expansion.

U.S.

The U.S. DNA synthesis market has been experiencing significant growth, largely driven by the increasing demand for synthetic DNA and RNA sequences for various applications. These include molecular research, diagnostics, and therapeutics. The market's competitive landscape is diverse, consisting of both established players and emerging companies that are eager to secure a share of this expanding market. The U.S. market is particularly influenced by advancements in personalized medicine and genetic therapies, which heavily rely on DNA synthesis for drug development, disease prevention, and treatment personalization.

Asia Pacific DNA Synthesis Market Trends

The DNA synthesis market in the Asia Pacific region is anticipated to grow at the fastest rate, with a CAGR of 17.50% from 2024 to 2030. This growth is attributed to the increasing demand for synthetic DNA in research, diagnostics, and therapeutics, along with the rising prevalence of genetic diseases and the growing need for personalized medicine.

China

China is expected to experience the highest growth rate in the DNA synthesis market, with a projected CAGR of 21.41%. Factors contributing to this growth include the rising number of contract research organizations (CROs) and the outsourcing of drug discovery and development activities by pharmaceutical and biotech companies. Additionally, China’s focus on expanding and upgrading its gene synthesis facilities is further accelerating market growth. For example, in May 2023, GenScript expanded its oligonucleotide manufacturing facility in Jiangsu, China, to enhance its production capacity.

Japan

Japan is also expected to witness significant growth due to its aging population and emphasis on personalized medicine. As a leader in scientific research, especially in biotechnology and biopharmaceuticals, Japan has a strong focus on genetic studies and gene expression profiling, which are crucial to the DNA synthesis market. These factors are expected to further drive the demand for DNA synthesis in the region.

India

The DNA synthesis market in India is anticipated to grow rapidly due to the country’s high birth rate and the significant prevalence of genetic disorders, exacerbated by factors like consanguineous marriages and founder mutations. Government initiatives, such as the "Make in India" program and biotechnology R&D grants, are empowering domestic players and attracting foreign investments. Notably, the Department of Biotechnology (DBT) launched the UMMID initiative in 2019 to address inherited genetic diseases in newborns, further stimulating the DNA synthesis market.

Europe DNA Synthesis Market Trends

Europe represents another key region in the DNA synthesis market. This is largely due to strong government support, continuous advancements in research infrastructure, and an increasing prevalence of chronic diseases like cancer, cardiovascular conditions, and genetic disorders. The growing adoption of gene therapy is also contributing to the market's growth.

UK

The DNA synthesis market in the UK is poised for growth, driven by ongoing research and innovation in genetics and molecular studies. Government initiatives and strong healthcare infrastructure provide a conducive environment for biomedical research. For instance, in November 2023, the UK's approval of the CRISPR-based gene-editing therapy Casgevy marked a significant milestone, positioning the UK DNA synthesis market for further growth.

France

France faces a significant burden from cancer, which remains a leading cause of death in the country. The demand for DNA synthesis in France is driven by its growing role in cancer diagnostics and personalized medicine, particularly through gene expression profiling and liquid biopsies. Furthermore, cardiovascular diseases, such as atherosclerosis and heart failure, are contributing to the growing interest in oligonucleotides and genetic profiles for both diagnostic and therapeutic purposes, pushing the demand for DNA synthesis technologies.

Germany

Germany’s DNA synthesis market is expected to grow due to the country’s strong R&D focus in diagnostics and therapeutics. Germany is actively promoting biotechnology and healthcare infrastructure through initiatives like “Industrie 4.0” and providing grants for R&D. These efforts not only boost the domestic market but also attract foreign investment, further driving the DNA synthesis market in Germany.

Browse through Grand View Research's Category Biotechnology Industry Research Reports.

The global exosomes market size was estimated at USD 177.4 million in 2024 and is anticipated to grow at a CAGR of 28.73% from 2025 to 2030.

The global cell culture media storage containers market size was estimated at USD 2.11 billion in 2024 and is projected to witness a CAGR of 12.55% from 2025 to 2030.

Key DNA Synthesis Companies:

Thermo Fisher Scientific, Inc

Twist Bioscience

BIONEER CORPORATION

Eton Bioscience, Inc.

LGC Biosearch Technologies

IBA Lifesciences GmbH

Eurofins Scientific

Integrated DNA Technologies, Inc.

Quintara Biosciences

GenScript

Order a free sample PDF of the DNA Synthesis Market Intelligence Study, published by Grand View Research.